6 Genome Sequencing Stocks to Buy for Big Health-Care Profits
Genome sequencing – basically figuring out the order of DNA, the building blocks of life – was once essentially little more than a lab exercise.
Genome sequencing – basically figuring out the order of DNA, the building blocks of life – was once essentially little more than a lab exercise. But now, it has reached commercial viability and then some.
The field of genomics goes back to the 1950s, though it really started in earnest with the start of the Human Genome Project in 1990 – a 13-year, $2.7 billion enterprise that was completed in April 2013.
Genome sequencing, in which scientists and their myriad machines detail the entire set of human DNA, has fantastic medical potential, allowing researchers to find genetic mutations – errors that can be harmless at times, but other times debilitating or even fatal. Moreover, genome sequencing is starting to reach realistic pricing – the costs have fallen down to about $1,000 at the low end, and companies are racing to cash in on the myriad opportunities.
Here are six genome sequencing stocks to buy for this emerging medical technology. While genomics isn’t the biggest investing buzzword today, this is a promising niche of the market that could take off as it gains more prominence.
Data is as of Dec. 20, 2018.
- Market value: $43.0 billion
- Illumina (ILMN, $292.25) sells gene sequencing equipment and array technologies. It’s a leader in the growing market for gene sequencing technology, focusing on the fields of prenatal testing, rare diseases, oncology, population genomics and consumer genomics.
Population genomics is large-scale comparison of DNA sequences of the population by governments and research labs. Meanwhile, consumer genomics is the backbone of growing consumer-facing companies such as 23andMe and Ancestry.com – brands you likely saw heavily advertised during the 2018 holiday season.
Illumina’s big advantage is its installed base of nearly 11,600 systems, found in hospitals, research labs and medical facilities. This equipment is relatively expensive, and carries per-use costs, but the investment the customers make in Illumina technology is what makes switching to a different platform less likely. This installed base gives Illumina runway to grow as genome sequencing takes off. As an example, Illumina genotyped more than 7 million consumer samples in 2017 – approximately equal to its total volume since 2007.
The company has grown revenues at a compound annual rate of approximately 22% since that point. Moreover, Illumina has demonstrated it can capitalize on its lead, generating more than $500 million in free cash flow each year since 2014.
Analysts at Bank of America/Merrill Lynch expect Illumina’s recent $1.2 billion acquisition of Pacific Biosciences to bolster its position in DNA sequencing through lower costs and increased output.
As genome sequencing grows, so grows Illumina.
- Market value: $2.1 billion
- Myriad Genetics (MYGN, $28.64) sells products in a growing niche known as personalized medicine. Myriad’s diagnostics products help consumers understand their odds of eventually getting a particular disease, and provide a pathway for determining which treatment options may prove most effective.
Myriad has a solid franchise in cancer testing with a reputation for accuracy and a large database of variants that helps the company maintain premium pricing. Helping patients find the most effective antidepressant medication may be an even larger opportunity for Myriad. While cancer testing is a $4 billion market with 1.5 million patients, the antidepressant market is two-and-a-half times larger, with approximately 8 million patients.
Myriad’s GeneSight personalized genetic testing has gained favorable reimbursement coverage from insurers based on estimated savings of nearly $3,300 for patients using its tests. Moreover, it represents an important step in diversifying its product portfolio.
Since 2014, Myriad’s revenues and earnings have been flat to slightly negative. However, as its products diversity and its reimbursement coverage continue to improve, the stock is poised for upside.
- Market value: $2.2 billion
- Genomic Health (GHDX, $59.89), as its name suggests, is a leader in genetic testing. The company achieved profitability in 2017 after years of investing heavily in its products, salesforce and international expansion. And as the company leverages the infrastructure its built, and the overall market for genomic testing grows, the setup for growth is excellent.
Genomic Health is focused exclusively on the oncology market. Its tests, which range in cost from $4,000 to $4,500, “definitely identify who does and who does not benefit from chemotherapy,” according to the company’s investor presentation. This saved the U.S. health-care system roughly $5 billion in 2017, which in turn drives insurance coverage rates for its signature Oncotype DX suite of tests for breast, colon and prostate cancers. Approximately 90% of “insured lives” are covered for Oncotype tests.
Internationally, the opportunity may be even larger. Covered lives in its current markets, which include Canada, the U.K., France and Spain, are approximately 220 million, according to company estimates. These will increase to 490 million covered lives in 2020 and beyond through increased insurance coverage in entrance into new markets., including Japan, Italy and Germany.
Revenue growth has been tepid over the past five years, growing from $263 million in 2013 to $341 million in 2017. Profitability was achieved in 2017 on an “adjusted basis,” but better is that the company has been profitable without accounting shenanigans through the first nine months of 2018. Next year may see Genomic Health capitalizing on all of the opportunities genomics offers.
CFRA analysts expect the company’s investments in its salesforce, international expansion and a new genetics division to sustain its profit growth.
- Market value: $20.7 billion
- Agilent Technologies (A, $65.19) is another non-pure play on genomics. In fact, it’s a big, somewhat complicated company that participates in a variety of markets, including diagnostics, pharma, academic/government, food energy and environmental. The company’s lab services and laboratory equipment divisions together account for most of its revenue at about 83%.
The Diagnostics and Genomics Group (DGG) participates in Agilent’s fastest-growing end markets, which on average are expanding at 3% to 5%, versus 5% to 7% for DGG. Since 2015, Agilent has been able to grow its genomics business at 8% annually on average, while increasing its operating margins from 9% to 23%, as of the 2018 fiscal year ended Oct. 31.
Agilent has proven competent in using mergers and acquisitions to prop up various parts of its business, and that includes genomics. Agilent bought Lasergen for $105 million in April 2018, two years after taking a 48% stake in the company. Lasergen gives Agilent greater access to the global molecular diagnostics market, via techniques used to analyze biological markers in the genome. That market is projected to reach roughly $10 billion by 2021.
- Market value: $6.8 billion
The market for genomic testing is promising, and as the previous slides indicate, there are plenty of entrants. By contrast, Sarepta Therapeutics (SRPT, $101.79) is capitalizing on advances in genome technology to provide gene therapy to an increasing number of rare diseases.
In June, Sarepta presented strong results from a gene therapy for Duchenne muscular dystrophy (DMD), a muscle-wasting disease. The company’s gene therapies are also used to treat Limb-girdle muscular dystrophy (LGMD), and it is forming a partnership to develop other treatments for the above diseases, as well as diseases of the central nervous system.
The company’s flagship eteplirsen for treatment of DMD was approved in 2016 and is anticipated to deliver approximately $300 million sales in 2018. And Sarepta has a deep pipeline to boot. The company currently is developing 21 therapies for rare muscular diseases. To wit, analysts at Bank of America/Merrill Lynch predicate their “Buy” rating on SRPT on the company building its core revenue stream with new products.
- Market value: $1.5 billion
- Spark Therapeutics (ONCE, $40.01), a gene therapy company, launched Luxturna – a treatment for certain types of genetically driven blindness – in the U.S. this year, with strong success so far. The drug contributed $4.3 million in net sales to the company’s $25.2 million in total revenues – all the rest was driven by agreements with Pfizer (PFE).
There is also a much larger opportunity for Spark to develop a one-time treatment for hemophilia. In August 2018, the company updated results for hemophilia A therapy and handed off development of its hemophilia B drug to Pfizer (PFE). The World Federation of Hemophilia says about 150,000 people worldwide are inflicted with hemophilia A and about 30,000 people are inflicted with hemophilia B.
Spark’s revenues are expected to explode from $12.1 million last year to $81.3 million in 2018, followed by a more modest (but still robust) 36% improvement to $110.4 million.